- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00114088
Surgical Treatments Outcomes Project for Dysfunctional Uterine Bleeding (STOP-DUB)
June 23, 2005 updated by: Agency for Healthcare Research and Quality (AHRQ)
STOP-DUB is a multicenter randomized clinical trial that is assessing the efficacy and effectiveness of hysterectomy versus endometrial ablation (EA) for dysfunctional uterine bleeding (DUB) in women for whom medical management has not provided relief.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The Surgical Treatments Outcomes Project for Dysfunctional Uterine Bleeding (STOP-DUB) is a multicenter, randomized clinical trial that assessed the efficacy and effectiveness of hysterectomy versus endometrial ablation (EA) for dysfunctional uterine bleeding (DUB) in women for whom medical management has not provided relief.
Institutional review board-approved study sites included the coordinating center, chair's office, the American College of Obstetricians and Gynecologists, and 33 clinical centers in the United States and Canada.
STOP-DUB enrolled (1) 237 eligible patients for whom medical treatment had not been successful and who were randomized to either hysterectomy or EA; and (2) an observational cohort of 139 patients who were "provisionally ineligible" or who were eligible but did not wish to be randomized.
Enrollment began November 25, 1997 and ended June 30, 2001.
Randomized women were followed using telephone interviews at least 2 years and observational women were followed a maximum of 6 months.
We also collected information on return clinical center visits and hospital bills from the sites directly.
The primary outcome addressed by the randomized trial is the impact of surgery on bleeding, pain, fatigue, and the major problem (symptom) that led the woman to seek treatment for her condition, measured 1 year following surgery.
Additional outcomes included the impact of surgery at time points after 1 year; changes in quality of life, activity limitation, sexual functioning, and urinary incontinence; surgical complications; additional surgery; and resource utilization.
The costs and the relative cost-effectiveness of the two surgeries will be calculated.
The main scientific objective for the observational study was to examine changes over time in terms of treatment selected, DUB-related symptoms, and quality of life.
Enrolled women signed an informed consent to participate.
Study Type
Interventional
Enrollment
242
Phase
- Phase 3
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Abnormal uterine bleeding in the absence of structural pathology, pharmacologic agents, IUD use, or systemic disorders of hemostasis that could explain the condition.
Exclusion Criteria:
Prescreen
- Age < 18 years
- Postmenopausal status (or bilateral oophorectomy)
- Bleeding not considered excessive by woman
- Desire to retain fertility
- Refusal to consider surgery
- Known myoma (from prior examination)
Eligibility Screen
- Lack of willingness to have a gynecologic or ultrasound examination
- Lack of willingness to be interviewed about bleeding or consider study
- Pregnancy
- Prior endometrial resection or ablation
- Prior myomectomy, myolysis, or hysterectomy
Medical History
- No tentative diagnosis of DUB
- History of malignancy of vagina, cervix, endometrium, or ovary
- History of complex endometrial hyperplasia or simple hyperplasia with atypia
- Current use of tamoxifen
- < 6 months since onset of excessive uterine bleeding
- < 9 months since stopping the use of IUD
- < 9 months since stopping the use of implantable hormone agent
- < 18 months since stopping use of Depo-Provera
- < 6 months of anovulatory DUB after reaching euthyroid status for woman with diagnosis of hypothyroidism
- < 3 months since pathology results indicate presence of endometrial polyp
Baseline Gynecologic Examination
- Enlarged (>= 14 weeks gestational age) uterus
- Focal bleeding of genital, urinary, or gastrointestinal tract
Ultrasound Examination
- Presence of any submucosal myoma
- Presence of any myoma >= 3 cm, any location
- Presence of > 3 myomas, any size or location
- Presence of endometrial polyp(s)
- Malignancy of the vagina, cervix, endometrium, or ovary
Laboratory and Ancillary Tests
- FSH level in women ages > 45 years confirming postmenopausal status
- Abnormal urinary tract or gastrointestinal tract imaging related to uterine bleeding
- Evidence of cervical cancer (screened by Pap smear in last 12 months and confirmed by colposcopy)
- Evidence of complex endometrial hyperplasia or simple hyperplasia with atypia or endometrial cancer (endometrial biopsy in last 12 months)
- Any test value inconsistent with a diagnosis of DUB
- Any test values, unlikely to change, compromising patient safety for surgery
Other
- Any existing medical condition, unlikely to change, putting patient at excessive risk for surgery
- Request for prophylactic bilateral oophorectomy by woman aged <45 years
- Lack of willingness to comply with study requirements
- Uncooperative behavior
- Any coexisting condition that may influence a patient's ability to comply with participation
- Refusal to allow evaluation or follow-up
- In process of scheduling surgery at time of baseline visit
Provisional Eligibility Criteria
- Refusal of randomization
- < 3 months of medical management (excluding GnRH agonist therapy) within the past 2 years
- Ongoing evaluation or treatment for abnormal cervical cytology (including endocervical polyps)
- Gastrointestinal or urinary tract condition unrelated to uterine bleeding currently being treated
- Any temporary test value compromising patient safety
- Any temporary existing medical condition putting patient at excessive risk from surgery
- Any coexisting condition requiring surgery (except tubal occlusion for any woman or oophorectomy for women >= 45 years of age)
- Lack of willingness to proceed with surgery at this time
- Lack of willingness to proceed with surgery likely to result in infertility
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Randomized trial: Impact of surgery on bleeding, pain,
|
fatigue, and major problem (symptom) leading the woman to seek treatment for her condition.
|
Observational study: changes over time in treatment selected, DUB-related symptoms, and quality of life.
|
Secondary Outcome Measures
Outcome Measure |
---|
Randomized trial: Impact of surgery on primary outcomes at time points after 1 year, quality of life, activity limitation, sexual functioning, urinary incontinence, surgical complications, additional surgery, resource utilization.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Kay Dickersin, PhD, Brown University
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Dickersin K, Munro M, Langenberg P, Scherer R, Frick KD, Weber AM, Johns A, Peipert JF, Clark M; Surgical Treatments Outcomes Project for Dysfunctional Uterine Bleeding Research Group. Surgical Treatments Outcomes Project for Dysfunctional Uterine Bleeding (STOP-DUB): design and methods. Control Clin Trials. 2003 Oct;24(5):591-609. doi: 10.1016/s0197-2456(03)00023-0.
- Weber AM, Munro MG. Endometrial ablation versus hysterectomy: STOP-DUB. Medscape Womens Health. 1998 May;3(3):3.
- Frick KD, Clark MA, Steinwachs DM, Langenberg P, Stovall D, Munro MG, Dickersin K; STOP-DUB Research Group. Financial and quality-of-life burden of dysfunctional uterine bleeding among women agreeing to obtain surgical treatment. Womens Health Issues. 2009 Jan-Feb;19(1):70-8. doi: 10.1016/j.whi.2008.07.002.
- Dickersin K, Munro MG, Clark M, Langenberg P, Scherer R, Frick K, Zhu Q, Hallock L, Nichols J, Yalcinkaya TM; Surgical Treatments Outcomes Project for Dysfunctional Uterine Bleeding (STOP-DUB) Research Group. Hysterectomy compared with endometrial ablation for dysfunctional uterine bleeding: a randomized controlled trial. Obstet Gynecol. 2007 Dec;110(6):1279-89. doi: 10.1097/01.AOG.0000292083.97478.38. Erratum In: Obstet Gynecol. 2008 Aug;112(2 Pt 1):381.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 1997
Study Completion
January 1, 2004
Study Registration Dates
First Submitted
June 13, 2005
First Submitted That Met QC Criteria
June 13, 2005
First Posted (Estimate)
June 14, 2005
Study Record Updates
Last Update Posted (Estimate)
June 24, 2005
Last Update Submitted That Met QC Criteria
June 23, 2005
Last Verified
June 1, 2005
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 5U01HS009506 (U.S. AHRQ Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Menorrhagia
-
BayerCompletedIdiopathic MenorrhagiaCroatia, Saudi Arabia, Bulgaria, Jordan, Romania, Russian Federation, Turkey, United Arab Emirates, Kuwait, India, Pakistan, Serbia, Sri Lanka
-
BayerCompletedIdiopathic MenorrhagiaCroatia, South Africa, Colombia, Czech Republic, Jordan, Lebanon, Macedonia, The Former Yugoslav Republic of, Moldova, Republic of, Romania, Ukraine, Venezuela, Bosnia and Herzegovina, Syrian Arab Republic, Albania
-
Legacy Health SystemUnknownMenopause | Climacteric; Menorrhagia, MenopausalUnited States
-
Minerva Surgical, Inc.CompletedMenorrhagia Due to Benign CausesHungary
-
Minerva Surgical, Inc.CompletedMenorrhagia Due to Benign CausesMexico
-
Minerva Surgical, Inc.CompletedMenorrhagia Due to Benign CausesCanada
-
Faculty of Medicine, SousseCentre Hôpital Universitaire Farhat HachedCompletedMetrorrhagia | Hysterectomy | Heavy Menstrual Bleeding | Abnormal Uterine Bleeding | Menorrhagia; PostmenopausalTunisia
-
University of Sao PauloRecruitingCardiovascular Diseases | Arterial Hypertension | Postmenopausal; MenorrhagiaBrazil
-
BayerCompletedMenorrhagia, DysmenorrheaJapan
-
University of Sao PauloRecruitingMotor Activity | Physical Inactivity | Postmenopausal; MenorrhagiaBrazil
Clinical Trials on hysterectomy
-
Southern Medical University, ChinaRecruiting
-
Queensland Centre for Gynaecological CancerNational Health and Medical Research Council, Australia; Johnson & Johnson... and other collaboratorsCompletedEndometrial CancerUnited Kingdom, Australia, Hong Kong, New Zealand
-
University Hospital, GhentCompletedOutpatient Hysterectomy in TransmenBelgium
-
University of Texas Southwestern Medical CenterCompletedEndometriosis | Pelvic Pain | Adenomyosis | Metrorrhagia | Pelvic Inflammatory Disease | Leiomyoma | MenorrhagiaUnited States
-
Nykøbing Falster County HospitalZealand University Hospital; Rigshospitalet, Denmark; University of Southern...Completed
-
Hospital Universitari Vall d'Hebron Research InstituteCompletedSurgery--Complications
-
Mansoura UniversityCompleted
-
Mayo ClinicTerminated
-
Chen ChunlinUnknownCervical CancerChina
-
Imelda Hospital, BonheidenCompleted